Starling Oncology, Inc.
STLN
NASDAQ6.40
USD
+0.09
- -
CIK
0001799191
ISIN
US68236X1000
CUSIP
68236X100
Return %
Stock
S&P500
1Y
10.34
19.43
3Y
10.34
76.01
5Y
10.34
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 641
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 18000 Studebaker Road, Suite 800 Cerritos CA United States of America 90703
- IPO Date
- Aug 4, 2026
- CIK
- 0001799191
- Website
- starlingoncology.com
- Similar Companies
- Business
- Starling Oncology, Inc. engages in the development and commercialization of targeted cancer therapies and related oncology solutions. The company designs, manufactures, licenses, and distributes pharmaceutical products and biologics focused on oncologic indications, including monoclonal antibodies, antibody-drug conjugates, small molecule inhibitors, and companion diagnostic tools. It provides oncology therapeutics across multiple lines, including late-stage clinical programs and approved treatments, with a portfolio spanning solid tumor and hematologic malignancy indications. The firm develops, sources, manufactures, and commercializes its products through collaborations and direct distribution channels. Main products and services: core oncology therapeutics and diagnostic solutions; research and development services in oncology, including preclinical and clinical development support; manufacturing and process development for biologics and small molecules; regulatory affairs and pharmacovigilance; commercialization activities including product launches, market access, and physician education; companion diagnostics and precision medicine services; strategic partnerships and licensing agreements; contract development and manufacturing organization (CDMO) services for third-party customers; portfolio management and life-cycle management of oncology assets. Latest major company changes: forms strategic partnerships and alliances with pharmaceutical and biotechnology collaborators to advance pipeline programs; completes funding rounds and secures additional capital to support clinical development and manufacturing scale-up; advances or completes acquisitions or asset purchases related to oncology portfolios; launches new product candidates or expands indications for existing therapies; undergoes corporate reorganizations or branding updates to reflect strategic focus; initiates significant operational scaling, including manufacturing capability expansions and geographic market entries within the last 1–2 years. Additional context: industry and business segments include oncology therapeutics, diagnostics, and life sciences services; targets hospitals, specialty clinics, and research institutions with oncology patient populations; geographic operations span North America, Europe, Asia-Pacific, and other international markets; founded in [year], headquartered in [location], with potential subsidiaries and parent relationships as part of a broader corporate group; maintains collaboration networks, including licensees, contract manufacturers, and research partners.
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates